Viatris should receive a pan-European marketing authorization for its Kixelle (insulin aspart) biosimilar rival to NovoRapid, the Committee for Medicinal Products for Human Use within the European Medicines Agency has recommended in a positive opinion.
Viatris’ Insulin Aspart Endorsed By EMA
Kixelle Biosimilar Rival To NovoRapid Receives CHMP Positive Opinion
Viatris has received a positive opinion from the EMA’s CHMP recommending granting a pan-European marketing authorization for the firm’s insulin aspart biosimilar rival to NovoRapid.
